What a Foreign Supply Chain in China Looks Like: From Dairy to Medical Devices, R&D

Summary

New Zealand companies are building complete supply chains in China, from R&D to distribution. Fonterra has established five application centres and one innovation centre in China. Fisher & Paykel Healthcare has located its third global manufacturing base in Guangzhou.

Zespri set up the New Zealand-China Kiwifruit Joint Laboratory in 2014 with the New Zealand Institute for Plant and Food Research and the Sichuan Academy of Natural Resource Sciences, and jointly established a kiwifruit breeding centre in 2021. Zespri operates warehousing centres in Beijing, Shanghai and Guangzhou, and in 2023 introduced a new cold-chain service to Dongguan's Shatian Port, cutting customer delivery times to 11 days. This year it will run 25 cold-chain services across three ports: Shatian, Shanghai Nangang and Damaiyu Port in Taizhou, Zhejiang.

Silver Fern Farms has 14 processing plants and centres in New Zealand, employs more than 6,000 staff at peak season, and connects a supplier network of over 16,000 farmers. Comvita has 400 sales points, and Les Mills has 10,000 instructors. These cases show that foreign investors are building capabilities in China, not just selling products into the market.

Commentary

Leading New Zealand companies are embedding R&D, manufacturing and distribution capabilities deep into the Chinese market, a trend that offers both lessons and challenges for smaller local firms. Fonterra's five application centres and one innovation centre in China reflect how dairy competition has shifted from raw material exports to localised innovation. Chinese dairy companies such as Yili and Mengniu are rising fast in chilled fresh milk and cheese, forcing foreign players to iterate products closer to consumers.

Fisher & Paykel Healthcare's decision to place its third global manufacturing base in Guangzhou highlights the regional reorganisation of medical device supply chains: China offers not only cost advantages but also a fast-responding engineering talent pool and vast clinical data resources. For NZ SMEs, the risk of relying solely on export agents is rising. They could explore sharing cold-chain, channel or R&D platforms with New Zealand companies already in China to lower entry barriers.

Zespri's case is particularly telling: its joint laboratory and breeding centre keep part of the intellectual property in China, while its cold-chain service through Dongguan's Shatian Port cuts delivery times to 11 days. This combination of localised R&D and autonomous logistics has helped Zespri maintain about 70 percent share of China's kiwifruit import market. However, China's domestic kiwifruit industry is improving quality rapidly with government support, and Zespri's breeding cooperation also faces trade-offs over technology spillover.

Silver Fern Farms connects more than 16,000 farmer suppliers, and its China strategy focuses on premium red meat channels. But China's share of New Zealand's total red meat exports has fallen from 38 percent in 2020 to about 30 percent in 2025, signalling pressure to diversify markets. Comvita's 400 sales points and Les Mills' 10,000 instructors represent asset-light models: the former relies on cross-border e-commerce and daigou channels, while the latter expands rapidly through licensed training.

Both, however, must contend with cost-effective competition from local Chinese brands.

Keywords: foreign supply chain, Fonterra, Zespri, Fisher & Paykel Healthcare, Silver Fern Farms, R&D and manufacturing, cold-chain logistics, kiwifruit breeding centre

Source: Three Cobblers Report